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A growing body of evidence have linked two of the most common aged-related 
diseases, type 2 diabetes mellitus (T2DM) and Alzheimer disease (AD). It has led to 
the notion that drugs developed for the treatment of T2DM may be beneficial in 
modifying the pathophysiology of AD. As a receptor agonist of glucagon- like peptide 
(GLP-1R) which is a newer drug class to treat T2DM, Geniposide shows clear effects 
in inhibiting pathological processes underlying AD, such as and promoting neurite 
outgrowth. In the present article, we review possible molecular mechanisms of 
geniposide to protect the brain from pathologic damages underlying AD: reducing 
amyloid plaques, inhibiting tau phosphorylation, preventing memory impairment and 
loss of synapses, reducing oxidative stress and the chronic inflammatory response, 
and promoting neurite outgrowth via the GLP-1R signaling pathway. In summary, the 
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Alzheimer’s disease (AD) is the most common neurodegenerative disorder of 
progressive cognitive decline in the aged population. The characteristic pathological 
hallmarks are abundance of two abnormal aggregated proteins in brain tissue: 
neurofibrillary tangles (NFTs) composed mainly of the microtubule-associated protein 
tau and amyloid plaques composed of insoluble amyloid-β (Aβ) deposits, synaptic and 
neuronal loss as well as dysfunction associated to the neurochemical changes in brain 
tissue (Mathis et al., 2007). The multiple molecular pathogenic changes contributing 
to the pathological hallmarks of AD include mitochondrial dysfunction, oxidative 
stress, endoplasmic reticulum (ER) stress, and inflammation, which lead to the 
varying levels of plaques and tangles, and these studies also explain the relationships 
between protein aggregation and neuronal loss in neurodegeneration (Meares et al., 
2011; Stalder et al., 1999).  
Current pharmacotherapy of AD is limited to cholinesterase inhibitors and the 
N-methyl-D-aspartate antagonist memantine. Although these drugs have been shown 
to treat the symptoms of AD they have not been shown to cease or reverse the 
pathophysiological causes of AD (Tan et al., 2014; Werner and Altaf, 2015). Present 
medications approved by the FDA do little to slow disease progression and provided 
no indication for the underlying progressive loss of synaptic connections and neurons 
(Wright et al., 2014). Thus, it is of great importance to seek novel therapeutic agents. 
To find new medications to treat AD based on our molecular pathology knowledge of 
AD has become a priority in the AD area of research. Priority candidate treatments for 
which there is considered to be a high level of supportive evidence, such as 
antihypertensives, antibiotics, antidiabetic drugs and retinoid therapy, have been 
summarized and described (Corbett et al., 2012). 
Considering T2DM had been identified as a risk factor for AD, It is possible to 
develop drugs that can treat T2DM to also treat AD. Use of long-lived mimetics of the 
glucagon like peptide-1 (GLP-1) that are resistant to cleavage by proteases is a 
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successful strategy to treat T2DM. In the present review, we explore a possibility to 
develop a new strategy to treat AD using receptor agonists of GLP-1R and explain the 
possible molecular mechanism. Epidemiological studies found a correlation between 
an increased risk of developing AD and T2DM (Biessels et al., 2006; Haan et al., 
2006; Ristow et al., 2004). Further research showed a range of shared 
pathophysiological changes seen in T2DM and AD (Akter et al., 2011). The possible 
common or interactive processes in T2DM and AD have been reviewed (Li et al., 
2007; Nelson et al., 2005).  
There are currently clinical trials ongoing that test the effectiveness of 
‘antidiabetic’ drugs in AD patients. We are aware of two ongoing pilot studies of 
GLP-1 analogs for AD. A clinical trial of Exendin-4 in AD is performed by the 
National Institute on Aging (ClinicalTrials identifier: NCT01255163). The other is 
evaluating liraglutide in Alzheimer's Disease (ELAD) conducted by the Imperial 
College London (ClinicalTrials identifier: NCT01843075). Three metabolic hormones 
have shown promise in preclinical models of AD: amylin, leptin and GLP-1. The 
neuroprotective effects of GLP-1 and its analogs have shown considerable results in 
vivo and vitro (Hölscher, 2014a; Wang et al., 2010). The GLP-1 analog liraglutide 
showed protective effects from memory impairments in the amyloid precursor protein 
(APP) /presenilin-1 (PS1) mouse model of AD. The Aβ levels, plaque load, and the 
inflammation response in the brain were much reduced after treatment by liraglutide. 
Furthermore, memory formation and synaptic plasticity in the hippocampus was 
rescued by the drug (McClean et al., 2011). The drug also reversed some long-term 
damage in very old transgenic AD mice (McClean et al., 2014a). The newer GLP-1 
analogues lixisenatide also had these impressive neuroprotective effects (McClean et 
al., 2014b). A study characterized the effects of another GLP-1 receptor agonist, 
exendin-4, on stress-induced toxicity in neuronal cultures and on Aβ and tau levels in 
triple transgenic AD (3xTg-AD) mice with and without streptozocin (STZ)-induced 
diabetes (Li et al., 2010). Liraglutide, exendin-4 and lixisenatide are all on the market 
in Europe as treatments for diabetes. Together, these results indicated a potential effect 
of GLP-1R agonists in treating AD, particularly when associated with T2DM or 
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glucose intolerance (Hölscher, 2014b).  
Geniposide, a key component extracted from the fruit of Gardenia jasminoides 
Ellis, is a major iridoid glycoside considered to be responsible for various biological 
effects of the herbs, and its aglycon is genipin. Gardenia is a widely used Chinese herb 
for treatment of hepatic disease, inflammation disorders, contusions and brain 
disorders (Wang et al., 1992; Chen et al., 2010; Wang et al., 2012). Increasing studies 
have focused on the neuroprotective effect of geniposide in brain diseases, especially 
neurodegenerative disorders. Its protective effect from memory impairment and 
normalisation of objection recognition has been shown in animal behavioral 
experiments (Gao et al., 2014; Lv et al., 2014). Using a high throughput screen for 
GLP-1 receptor agonists, geniposide was identified as an agonist for the GLP-1 
receptor (Liu et al., 2006). It has been shown that the activation of the GLP-1 receptor 
by geniposide induces neurotrophic and neuroprotective effect in cells (Liu et al., 
2009, 2012). But the mechanisms underlying these effects have not been definitively 
identified. The aim of present review is to summarize a Chinese herbal medicine that 
can ameliorate AD symptoms and to investigate the cell and molecular mechanisms 
underlying its therapeutic efficacy based on AD pathogenesis hypothesis by which 
diabetes and abnormal glucose metabolism is involved in AD. 
 
2. Metabolism and pharmacokinetics  
 
Most herbal medicines which have been used in China, Korea, and Japan are orally 
administered. In general, glycosides which are the main contents in herbal medicines, 
are brought into contact with the intestinal microﬂora in the alimentary tract, where it 
is metbolised. Geniposide, an iridoid glucoside, is a major component ( ≥ 2%) in the 
fruits of Gardenia jasminoides Ellis. Until now, pharmacological studies of geniposide 
have revealed key properties including antitumor effects (Hsu et al., 1997), 
modulation of DNA expression (Galvez et al., 2005), treatment of pain (Gong et al., 
2014), anti-inflammatory, coloretic and hepatoprotective effects (Chen et al., 2009; 
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Liu et al., 2010; Chou et al., 2003; Ma et al., 2011). However, the precise mechanisms 
of its effects remains poorly understood. It was found that intestinal bacteria in 
animals can transform geniposide into its aglycone genipin or other metabolites (Fig. 
1) (Akao et al., 1994; Chen et al., 2008). Ten metabolites (G1–G10) involved in the 
metabolic processes were identified. It is interesting that all the metabolites detected 
were produced from the genipin or its ring-opened derivatives rather than the 
geniposide itself. It revealed that when geniposide was orally administered, 
geniposide was first hydrolyzed to genipin by β-glucosidases. After deglycosylation 
of geniposide in the liver or intestine, genipin would undergo redox or phase II 
metabolism immediately (Han et al., 2011). The metabolism of geniposide in vivo 
undergoes the following pathway: it is hydrolyzed first to produce the intermediate 
aglycone (genipin), which quickly conjugates with glucuronic acid as the predominant 
metabolite, followed a series of further metabolic reactions.  
Previous studies had reported the pharmacokinetics of geniposide after peroral 
administration and intravenous (i.v.) administration in mice (Hou et al., 2008; Ueno et 
al., 2001; Ye et al., 2006). More detailed information of the bioavailability and tissue 
distribution of geniposide is still lacking. Recently, studies on the pharmacokinetics, 
bioavailability and tissue distribution of geniposide had been carried out (Sun et al., 
2012; Wang et al., 2014). The major pharmacokinetics parameters of geniposide in rat 
plasma after oral administration are shown in Table 1 (Yu et al., 2013). Compared 
with the i.v. administration, the t1/2 was prolonged after oral administration of 
geniposide. In addition, The AUC0 →∞ values of geniposide were 6.99 ± 1.27 
h · μg/ml following i.v. administration of 10 mg/kg of geniposide. After oral 
administration of geniposide, the absolute oral bioavailability (%F) of geniposide was 
calculated as 9.67%, the AUC0 →4h values in tissues were in the order of kidney > 
spleen > liver > heart > lung > brain (Yu et al., 2013).  
Geniposide is widely used in Chinese medicine as a neuroprotection agent (Liu et al., 
2009; Wu et al., 2009). Pharmacokinetic studies of geniposide and its increased 
absorption in the brain by the terpene borneol have been published (see table 2 for 
details on the Pharmacokinetic parameters) (Yu et al., 2013). The results also 
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demonstrated that borneol markedly facilitated the delivery of geniposide to the 
hippocampus. Therefore, the region specific effect of borneol on the Blood Brain 
Barrier (BBB) might be a new strategy for the treatment of central nervous system 
(CNS) disorders. 
In order to better understand the pharmacokinetics of geniposide, its aglycone genipin 
was administered intravenously and orally. When genipin was given as an intravenous 
bolus, genipin levels declined rapidly and genipin sulfate emerged instantaneously, 
indicating that a very rapid hepatic sulfation had occurred (Hou et al., 2008). Further 
research needs to be performed on other similar iridoid compounds contained in 
various medicinal herbs to obtain a more comprehensive view of their 
pharmacological mechanism and metabolic fates. 
 
3. Molecular pathways  
 
The GLP-1 receptor belongs to the class B family of G protein-coupled receptors 
(GPCRs). A large number of studies have shown that GLP-1 functions through its 
receptor to regulate insulin secretion and glucose metabolism and is, therefore, an 
important strategy in the treatment of T2DM (Burmeister et al., 2012; Shao et al., 
2010). GLP-1 just like insulin and IGF-1 activates second messenger signaling 
pathways that are commonly linked to growth factor signaling (Holscher, 2014a). 
Geniposide is structurally unrelated to insulin and binds to GLP-1R, thereby 
circumventing insulin-signaling impairment. After binding to the GLP-1R, it activates 
signaling pathways that converge with the insulin-signaling pathway and facilitate 
insulin signaling. It was found that geniposide, with the activation of GLP-1 receptor, 
induced insulin secretion in a dose-dependent manner and showed neurotrophic 
properties by stimulating cAMP production. Furthermore, the phosphatidylinositol 
3-kinase (PI3K) signaling pathway and mitogen-activated protein kinases (MAPK) 
pathway are involved in the neuroprotection of geniposide against oxidative damage 
in PC12 cells and in SH-SY5Y cells (Liu et al., 2007; Liu et al., 2012; Guo et al., 
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2012; Sharma et al., 2013). The activities of geniposide in neurons include increased 
expression of genes that are linked to cell growth and repair, inhibition of apoptosis 
and reduction of inflammatory responses (see Fig. 2 for details on the underlying 
molecular mechanism). 
 
4. Possible neuroprotective mechanisms in AD 
4.1 Geniposide reduces levels of Aβ 
Plaques which are composed of aggregated Aβ (Aβ1-42–Aβ1-40) are a characteristic 
hallmark of AD. Aβ is a peptide fragment, mostly 40-42 amino acids in length, which 
is cleaved from the APP by β-secretases and γ-secretases (Thinakaran et al., 2008). 
Pimplikar (Pimplikar, 2009) summarized many avatars of the amyloid hypothesis in a 
review. It was originally proposed that increased levels of Aβ resulted in plaque 
formation which caused AD. Subsequent observations that familial APP mutations 
increase Aβ42 generation led to a proposal that it is the increased levels of Aβ42 peptide 
that causes AD. Another variation on the theme is that the absolute levels of Aβ42 are 
less important than the ratio of Aβ42/40 in causing AD (Pimplikar, 2009). Others 
propose that amyloid is not instrumental in the development of AD at all  (Morris et 
al., 2014). However, the currently most favored idea is that Aβ forms soluble 
oligomers, which are pathogenic in nature and cause AD (Selkoe, 2008).  
    Aβ aggregation into soluble oligomers are believed to be the main toxic species 
and the causative agent underlying the pathological mechanism for AD, aggregating 
and accumulating within and around neurons, cause cognitive dysfunction including 
memory loss (Selkoe, 2008; Rakez and Cristian, 2013). There is also evidence that the 
increased level of Aβ depresses excitatory synapses and reduces neuronal activity, and 
in contrast to the pathological accumulation in normal brain Aβ is produced at lower 
concentration (Kamenetz et al., 2003; Parihar and Brewer, 2010). As a downstream 
effect, tau pathology in AD associated with the cognitive impairment was initiated. 
It’s not surprising that the metabolism of Aβ has become an important therapeutic 
Neuroprotective effects of geniposide 
 
target in AD research. Understanding the processing and secretion of APP and its 
relationship to Aβ opens a window to develop compounds that prevent the production 
of Aβ by affecting the cleavage of APP, or the aggregation, clearance or toxicity of Aβ 
(Sabbagh et al., 2000). 
The iridoid glucosides extracted from Gardenia Jasminoides showed potential 
improvement of short-term learning/memory capacities in human Aβ42 –expressing 
transgenic flies (Yu et al., 2009). It suggests that the component of Gardenia 
Jasminoides might have potential protective effect against neurodegenerative 
processes in AD. Pre-incubation with geniposide prevented primary cultured cortical 
neurons from Aβ1-42-induced injury. Geniposide also induced the expression of 
insulin-degrading enzyme (IDE), a major degrading protease of Aβ, in a 
dose-dependent manner (Yin et al., 2012). These findings indicate that geniposide 
activates GLP-1 receptors, which then protects against Aβ-induced neurotoxicity by 
regulation of the expression of IDE in cortical neurons. The cultured hippocampal 
neurons had significantly degenerated after treatment with Aβ25-35, but the 
degeneration did not occur to the same extent in the presence of genipin (Yamazaki et 
al., 2001). One study found that genipin suppressed apoptosis in cultured cells via 
inhibition of caspase activation and mitochondrial function (Yamamoto et al., 2000). 
Furthermore, strong evidence suggests that geniposide regulates expression of 
apoptosis-related proteins via the MAPK signaling pathway, thereby overcoming the 
toxicity of Aβ (Liu et al., 2007). All of those studies indicate that geniposide and 
genipin are potential candidates for preventing the development of AD. 
 
4.2 Inhibition of Tau phosphorylation by geniposide 
Hyperphosphorylated tau protein was identified as the major component of 
neurofibrillary tangles, which are known to be a key pathological feature of AD 
(Grundke-Iqbal et al., 1986). Tau protein is a highly soluble microtubule-associated 
protein found in the axonal compartment of the neuron. Its primary function is 
involved in microtubule stabilization, axonal transport, homeostasis, and synaptic 
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function (Drubin and Kirschner, 1986; Terwel et al., 2002). Integrity of the 
microtubules is maintained by the phosphorylation state of tau, which is regulated by 
many phosphatases and kinases (Avila et al., 2004; Hashiguchi et al., 2013). GSK-3 
has been identified as the key kinase responsible for the hyperphosphorylation of tau 
in AD (Flaherty et al., 2000; Hooper et al., 2008; Llorens-Martín et al., 2014). When 
tau protein is phosphorylated, it results in the disassembling of microtubules and can 
aggregate abnormally when hyperphosphorylated to form neurofirillary tangles. Once 
the aggregation into neurofirillary tangles occurs, tau loses the function of connecting 
to tubulin and can no longer play a role in the microtubule assembly. Thus, inhibition 
of pathological hyperphosphorylation of tau may be a therapeutic target for AD (Iqbal 
et al., 2010; Ma et al., 2014).  
   Various animal models have enabled identification and characterization of key 
cellular processes that promote apoptosis in tauopathy, including synapse loss, 
impaired axonal transport, overstabilisation of filamentous actin, mitochondrial 
dysfunction, and aberrant cell cycle activation in post-mitotic neurons (Frost et al., 
2015). 
Identifying the causes of abnormal tau phosphorylation and aggregation is a major 
target for the development of therapeutic interventions for tauopathies, and has been 
the focus of much research, including AD (Götz et al., 2012; Medina et al., 2014). 
Current strategies include decreasing tau aggregation, blocking abnormal tau 
phosphorylation, or stopping the spread of tau pathology through the brain. Our 
previous study (Gao et al., 2014) showed that geniposide could greatly reverse tau 
hyperphosphorylation and the paired helical filament like structures (PHFs ) induced 
by STZ. Furthermore, we also showed that neuroprotective effect of geniposide was 
blocked by Wortmannin, a PI3k inhibitor. This indicates that signaling of PI3K/GSK3 
is involved in the phosphor-tau decrease effect of geniposide. 
 
4.3 Attenuation of mitochondrial oxidative stress by geniposide 
The multiple pathogenic mechanisms contributing to the pathology of AD include an 
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increase of reactive oxygen species (ROS) production, mitochondrial dysfunction, and 
apoptosis due to the impairment of mitochondrial Ca2+ handling ability, altered Ca2+ 
homeostasis, increased mitochondrial permeability transition pore opening, and 
promotion of cytochrome c release (Godoy et al., 2014). Studies using transgenic 
mice demonstrated alterations in mitochondrial enzymes in the AD brain (Piaceri et al., 
2012). It has been shown that one of the neurotoxic mechanisms of Aβ peptides is 
increasing oxidative stress in cultural neurons (Lee et al., 2010). Moreover, the 
enhancement of the oxidative stress by the in vivo depletion of vitamins has been 
shown to result in an increased amount of Aβ by the inhibition of it clearance from the 
brain (Habib et al., 2012). These suggest that oxidative stress, either by itself or as 
part of a “two step process”, causes neuronal dysfunction, and eventually AD (Ciron 
et al., 2012). Many treatment strategies have been focused on preserving 
mitochondrial function in AD. The underlying mechanism of action seems to be 
related to the prevention of mitochondrial Ca2+ overload, and modulation of the 
fusion-fission process, thereby arresting mitochondrial dysfunction (Dinamarca et al., 
2008). Induction of endogenous antioxidative proteins seems to be a reasonable 
strategy for delaying the progression of cell injury. 
It has been shown that intra-gastric administration of geniposide significantly 
reduces oxidative stress and increases the mitochondrial membrane potential and 
activity of cytochrome c oxidase in addition to improving learning and memory in 
APP/PS1 mice (Lv et al., 2014). Genipin was evaluated for its ability to inhibit 
oxidative effects in rat brain homogenate initiated by an Fe2 + / ascorbate system. It 
inhibited the generation of malondialdehyde, which reacts with 
N-methyl-2-phenylindole. Besides, genipin is a specific hydroxyl radical scavenger 
(Koo et al., 2004). Geniposide induced Glutathione S-transferase (GST) activity and 
the expression of GST M1 and GST M2 acting in primary cultured rat hepatocytes 
through the expression of MEK-1 signaling proteins and the activation of 
Ras/Raf/MEK-1 signaling pathway. Glutathione S-transferases (GSTs) are a family of 
dimeric enzymes which is responsible for the metabolism of a broad range of 
xenobiotics (Kuo et al., 2005).  
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    Geniposide activated the GLP-1 receptor, leading to an increase in intracellular 
cAMP. Furthermore, geniposide could increase the expression of HO-1 and resist the 
oxidative damage induced by H2 O2 and 3-morpholinosydnonimine hydrochloride 
(SIN-1) in PC12 cells by activating the MAPK -p90RSK, PI3K/Akt-Nrf2 and 
PKA-CREB (cAMP-response element binding protein) signaling pathways (Liu et al., 
2009; Liu et al., 2007;Yin et al., 2010; Yin et al., 2010). Pretreatment with geniposide 
markedly improved the cells’ viability and regulated the expression of apoptotic 
protein involved in mitochondrial mediated apoptosis in PC12 cells induced by CoCl 2. 
The results demonstrated that geniposide had a significant influence on the 
mitochondrial function which was damaged by oxidative stress induced by CoCl 2 
(Guo et al., 2009). Genipin has an ability to induce neurite outgrowth through 
activation of several protein kinases including extracellular signal-regulated kinase 
(ERK) and activation of nitric oxide synthase (NOS) in PC12h cells. Studies also have 
shown that the NO/cGMP pathway suppresses 6-OHDA-induced apoptosis in PC12 
cells by inhibiting the mitochondrial cytochrome c release, caspase-3 and -9 activation 
via PKG/PI3K/Akt-dependent Bad phosphorylation (Matsumi et al., 2008; Ha et al., 
2003) 
 
4.4 Inhibition of ER stress by geniposide 
The endoplasmatic reticulum (ER) is a membranous cell organelle in which key 
cell functions takes place such as protein synthesis, and folding and transport of 
translocating and integrating proteins (secretory and membrane proteins), lipid 
biosynthesis, and maintaining calcium homeostasis (Fagone et al., 2009; Sammels et 
al., 2010). Disturbance in ER function via the accumulation of unfolded and 
deficiently modified proteins, and release of ER luminal Ca2+ into the cytoplasm 
results in ER stress; chronic ER stress emerges as a key factor driving neuronal 
degeneration and cognitive impairment beyond cell death, a late event on disease 
progression, which has been linked to a variety of age-related neurodegenerative 
diseases, such as AD and Parkinson’s disease (PD) (Antero et al., 2009; Salminen et 
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al., 2010; Torres et al., 2014). A large body of evidence indicates that the ER stress 
response is localised to dendrites. This heterogeneity of the ER network may be 
related to axonal degeneration and synaptic loss in neurons, particularly in the case of 
redox-based dysfunctions, emphasizing a role for ER stress in neuronal degeneration 
(Raff et al., 2002; Murakami et al., 2007; Banhegyi et al., 2008). Mostly, reduction of 
amyloid plaques is correlated with attenuated ER-stress and vice versa. It is revealed 
that treadmill exercise (TE) prevented PS2 mutation-induced memory impairment and 
reduced Aβ-42 deposition and ER stress through the inhibition of β-secretase in the 
cortex and/or hippocampus of aged PS2 mutant mice. It showed that APP processing 
and phosphorylation of tau might be influenced by ER-stress signaling (Kristina and 
Sven, 2013). Therefore, elucidating ER-stress in AD might help turning the scale in 
therapeutic considerations or for evolvement of new highly diagnostic biomarkers. 
Currently, no evidence existas that geniposide and genipin suppresses ER stress 
that is induced by Aβ. However, several studies (Tanaka et al., 2009; Masayuki et al., 
2009) show the protective effects of genipin on cytotoxicity induced in Neuro2a cells 
by tunicamycin (TM), an ER stress inducer. Genipin dramatically rescued the cells 
against TM-induced cell death. In addition, genipin suppressed ER stress-induced 
upregulation of glucose-regulated protein of 78 kDa (GRP78, also known as Bip) and 
CCAAT/enhancer-binding protein(C/EBP) homologous protein (CHOP, also known 
as growth arrest and DNA damage-inducible gene 153(GADD153)), also suppressed 
the activation of caspase-3/7 and caspase 12. Another studyexamined the potential 
regulatory effects of geniposide on hepatic dyslipidemia and its related mechanisms in 
vitro and in vivo. The authors found geniposide inhibited palmitate-induced ER stress, 
reducing hepatic lipid accumulation through secretion of apolipoprotein B and 
associated triglycerides and cholesterol in human HepG2 hepatocytes (Lee et al., 
2013). Oral administration of geniposide also reduced in middle cerebral artery 
occlusion rat model (Pan et al., 2014) 
 
4.5 Inhibition of chronic inflammation in AD by geniposide 
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 Inflammation is a complex molecular and cellular defense mechanism in 
response to stress, injury and infection. Although the etiologic mechanisms of AD are 
poorly understood, more recently, analysis of human brain AD samples has shown 
highly expressed inflammatory cytokines and an upregulation in inflammatory genes 
during the early stages of AD (Hollingworth et al., 2011; Sudduth et al., 2013). During 
neurodegenerative disease development, microglia and other cell types, including 
cytokines, are activated in response to misfolded proteins in the brain, also participate 
in the active immune defense and are particularly important in regulating tissue 
homeostasis and in preserving the structural and functional characteristics of the brain 
(Heneka et al., 2014; Fakhoury, 2015). McGeer et al. (1998) demonstrated the 
activation of microglial cells and astroglial cells in close proximity to the damaged or 
dying neurons. The accumulation of glia cells around plaques along with strong 
upregulation of inflammatory markers has been taken as evidence that glia cell 
proliferation is a key element of the disease process. This is supported by several in 
vivo studies using markers for proliferating cells in transgenic mice. Elevated levels 
of inflammatory cytokines, TNFα, IFNγ, and interleukins, in particular IL-1β and 
IL-18, are found in the brain, near the Aβ plaques, in AD patients and transgenic mice 
(Johnston et al., 2011; Rubio-Perez et al., 2012).   
Modern medical practice has proved that some of Chinese herbal medicine can 
have anti-inflammatory effects in patients. Gardenia fruit extracts (GRE) contain 
acute anti-inflammatory activities, geniposide and genipin are possibly responsible for 
those activities of GRE (Koo et al., 2006). In treatment of various peripheral 
inflammation, genipin performs its anti-inflammatory activity though the suppression 
of both NO production and cyclooxygenase expression. Geniposide also decreases 
serum LPS level and inhibits cytokine (TNF-ɑ and IL-6) release in mice (Zheng et al., 
2010; Zhu et al., 2005). Several studies demonstrated that geniposide exerted 
anti-inflammatory effects by interfering with the expression of Toll-like receptors 4 
(TLR4), which subsequently inhibited the downstream NF-κB and MAPK signaling 
pathways and the release of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 
(Song et al., 2014; Wang et al., 2012; Huang et al., 2013).  
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Aβ acts as a microglia activator in cell culture studies (Meda et al., 1995). Genipin 
significantly repressed NO release from microglia that have been stimulated with Aβ. 
Nevertheless, more work is required on identifying target molecules of genipin 
involved in signaling pathways modulating the microglial inflammatory response. The 
receptor for advanced glycation end products (RAGE), an immunoglobulin-like cell 
surface receptor, is also known to be an important cellular cofactor for Aβ-mediated 
cellular perturbation (Yan et al., 2012). The mechanisms by which Aβ mediates 
activation of microglia and astrocytes remain to be elucidated. It appears that there is 
an important role for RAGE-mediated signaling in the microglial activation and 
neuronal dysfunction. RAGE triggers the generation of pro-inflammatory cytokines at 
the blood brain barrier (Leclerc et al., 2010). Further, RAGE dependent signaling in 
microglia stimulates inflammatory responses and processes that exacerbate neuronal 
damage, ultimately impairing neuronal function in the cultured cells taken from AD 
and AD transgenic mice (Yan et al., 2009; Fang et al., 2010; Lue et al., 2001). Recent 
studies demonstrate that geniposide significantly blocks RAGE-dependent signaling 
(activation of ERK and NF-κB) Aβ-induced along with the production of TNF-α and 
IL-1β. Notably, based on the data from co-immunoprecipitation assay, they infer 
that geniposide exerts protective effects on the Aβ-induced inflammatory response 
through blocking Aβ binding to RAGE and suppressing the RAGE-mediated signaling 
pathway (Lv et al., 2015). Taken those together, RAGE may be a target for a novel 
AD therapy. 
 
4.6 Neurite outgrowth promoted by geniposide 
Nerve growth factor (NGF), a neurotrophin, plays a trophic role both during 
development and in adulthood, and activates TrkA-Ras-ERK signaling pathway by 
interacting with the specific receptor tropomyosin kinase receptor A (TrkA) (Aloe et 
al., 2012; Huang et al., 2003; Patapoutian and Reichardt, 2001). Also, NGF elicits its 
neuritogenic effect through activation of nNOS followed by activation of 
NO-cGMP-PKG signaling pathway (Hartikka and Hefti, 1988). Further studies on 
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NGF deficit-induced neurodegeneration in transgenic mice demonstrated also a novel 
causal link between neurotrophic signaling deficits and AD (Cattaneo and Calissano, 
2012). There are growth cones at the free terminals of long neurites in PC 12 cells. 
Neurites induced by genipin generally seemed to be more branched than those 
induced by NGF. Addition of ERK kinase inhibitors could almost completely abolish 
the neurite induction. A neuritogenic effect of genipin in PC12h cells was also 
inhibited by the NOS inhibitor, NO scavenger, and PKC (cGMP-dependent kinase) 
inhibitor (Yamazaki et al., 1996, 2001, 2004). These findings suggest that NO 
production followed by cGMP-mediated stimulation of the MAPK cascade is 
implicated in the neuritogenesis by genipin in PC12 cells. Further, it seems that 
geniposide and genipin promote neuronal development via different molecular 
mechanisms. Normal PC12 cells have no nNOS even though PC12 cells and PC12h 
cells share the same origin. Treatment with geniposide promoted cellular growth, yet 
treatment with genipin did not (Yamazaki et al., 2006). This indicates that nNOS is the 
common target of geniposide and genipin, and that geniposide possesses additional 
therapeutic targets. Perry et al (Perry et al., 2002) was the first to describe the effects 
of GLP-1 and its long-acting analogue, exendin-4, on neuronal proliferation and 
differentiation, and on the metabolism of two neuronal proteins in PC12 cells, which 
had been shown to express the GLP-1 receptor. This study demonstrated that GLP-1 
and exendin-4 induced neurite outgrowth in a manner being similar to nerve growth 
factor (NGF). A significant increase on the GAP-43 protein level in parallel with 
neurite outgrowth was observed after treatment with geniposide. The data also 
demonstrate that geniposide induces the neuronal differentiation of PC12 cells via the 
MAPK pathway (Liu et al., 2006). Therefore, Geniposide has neuroprotective effects 
due to the activation of the GLP-1 receptor in cells without nNOS. It is speculated that 
there is a correlation between the effect of the two drugs and the structural difference 
(Liu et al., 2012). 
 
 




As a receptor agonist of GLP-1R, geniposide is a novel drug candidate for the 
treatment of AD because of its multiple effects in neuroprotection. As the world’s 
ageing population continues to increase and the treatment of AD is still a worldwide 
problem, the therapeutic potential of geniposide which may delay the onset of 
age-related disorders is highly desirable. The molecular mechanism and therapeutic 
targets of geniposide are not completely understood and require further research. 
Geniposide is water soluble and orally active and also can cross the 
blood-brain-barrier. It is easy to administer and has been shown to be safe to take. In 
the present review, we describe the possible mechanisms of the neuroprotective 
properties of geniposide and genipin: inhibiting Aβ toxicity, oxidative stress, 
mitochondrial damage, ER stress, inflammation and tau phosphorylation. In summary, 
the Chinese traditional medicine geniposide may be used as a novel treatment of 
sporadic AD and other diseases. Clinical trials in AD patients are warranted to test this 
hypothesis.  
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Table 1. Pharmacokinetic parameters of geniposide in plasma after oral administration 
Parameters Geniposide(40.65 mg/kg) 
Zhi‐Zi‐Hou‐Pu decoction  
Geniposide(100mg/kg) 
Tmax(min) 0.79±0.19 0.5±0.03 
Cmax(ug/ml) 1.29±0.16 1.40±0.24 
T1/2(h) 2.67±0.56 3.55±0.69 
AUC(0-∞) (h·ug/ml) 5.07±1.07 6.76±1.23 
(Yu et al., 2013) 
 
 
Table 2. Pharmacokinetic parameters of geniposide in brain regions after i.v. 
administration 
parameters  Cortex Hippocampus Hypothalamus Striatum 
Tmax(min) 24.00±8.94 20.00±0.00 20.00±0.00 20.00±0.00 
Cmax(ug/ml) 565.80±234.21 134.87±49.00 133.13±97.76 150.46±63.02 
T1/2(h) 1.84±0.80 2.62±2.03 1.69±1.34 2.12±0.75 
AUC(0-∞) (h·ug/ml) 796.67±240.00 400±240.00 298.33±96.17 441.67±109.17 
MRT(0-∞) (h) 2.04±0.77 3.85±2.79 2.69±1.43 3.25±0.85 
(Yu et al., 2013) 












Figure 2: Overview of the main pathways induced by geniposide in neurons 
Geniposide activated the GLP-1 receptor in a manner similar to GLP-1. The GLP-1 
receptor is a member of a different class of receptors compared with insulin receptor 
(IR). Activation of the GLP-1 receptor activates an adenylyl cyclase and increases 
cAMP levels (Green et al., 2004), which stimulates protein kinase A (PKA) and 
enhances the transcription of insulin receptor substrate 2 (IRS2) (Broca et al., 2009). 
By this pathway it can link with the signaling pathway of IR. Phosphorylation of PKA 
and other downstream kinases are related to insulin secretion and growth factor 
signaling. An increase of PI3K levels via the G protein activation can activate 
following pathways: (1) MAPK. This pathway activates gene expression, which 
controls expression of peptides that are required for cell growth and repair in neuronal 
cells (Perry et al., 2003) and also Erk1/2 and PI3k which also activate the MAPK 
pathway (Sharma et al., 2013). (2) geniposide also suppresses the induction of 
apoptosis. This pathway involves stimulation of PI3K binding to IRS and G protein, 
activation of PI3K and protein kinase B (Akt/PKB), which suppresses the induction of 
apoptosis and thereby protects neurons (Liu et al., 2012). (3) Activation of Glycogen 
Synthase Kinase (GSK3) to modify the cellular skeleton and dynamics by mediating 
the phosphorylation levels of tau protein; modulating cleavage of amyloid-beta 
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protein precursor (APP) and improve learning and memory formation 
(Eldar-Finkelman et al., 1999; Gao et al., 2011; Gao et al., 2014). As well, AMPK 
inhibits mTOR complex resulting in autophagy stimulation. This pathway also 
suppresses Glucose transporter 2 (GLUT-2) and GLUT-4 gene expression. 
Traditionally, insulin is associated with its blood glucose lowering activity. This is 
achieved by activating a glucose uptake transporter, e.g. GLUT-4. This function is 
only one of many of the IR and GLP-1R (Perry and Greig, 2005; Hölscher, 2011, 
2014). 
 
